Update and interpretation of the 2023.V1 and 2023.V2 NCCN clinical practice guidelines for Non-small cell lung cancer(NSCLC)LI Xin, REN Dian, JIA Chaoyi, CHEN Jun105-110
Influence of TP53 co-mutation on efficacy of targeted therapy for lung cancer with driver gene mutation and treatment strategiesSUN Dongchen, YANG Yunpeng111-115
Predictive value of plasma cytokines for the efficacy and prognosis of immunotherapy in NSCLC patientsLIANG Zhenyu, WAN Qiming, PENG Weiwei, SHEN Bo, ZHOU Guoren116-122
Impact of COVID-19 infection on the surgical treatment of lung cancerZHANG Tianxiang, ZHANG Ye, CUI Yong123-127
Safety of concurrent tumor treating fields and chemoradiation in patients with newly diagnosed glioblastomaLI Jintan, LU Hongyu, FAN Xiao, WANG Xiefeng, TAO Chao, YAN Wei, ZHANG Junxia128-132
Cancer-associated fibroblast-derived exosomes promote malignant invasion of prostate cancer through inhibition of ferroptosisZHAO Jun, MAO Liang, SHEN Jijie, SUN Hongbin133-140
Analysis of lymph node metastasis and risk factors in 11s group after lobectomy and lymph node dissection in patients with non-small cell lung cancerMAO Yu, BAI Yanyan, LI Ming, QIAO Wenting, ZHAO Suqing141-148
Analysis of risk factors related tobiochemical remission of patients with growth hormone-secreting pituitary adenomas treated by the endoscopic endonasal surgeryLU Yue, CHAO Xiaofeng, ZHANG Qi, MIAO Faan, FAN Yuechao149-152,157
Effects of different anastomotic methods on intestinal reconstruction in low anterior resection of rectal cancer on anorectal functionTIAN Junjun, HE Yun, PENG Lizhong153-157
Efficacy of Pabolizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer and its effect on tumor markers and gastrointestinal responseJIANG Shu, LI Chenghui, XIE Lili, WANG Aijuan158-161
